On September 8th, 2026, National Geographic featured insights from AFAR Board Member and multiple Grantee Nir Barzilai, MD, on the potential for GLP-1 drugs as gerotherapeutics to treat or delay age-related diseases and extend healthspan.
In addition to serving on AFAR’s Board of Directors, Dr. Barzilai is the 2026 recipient of AFAR’s George M. Martin Lifetime Achievement in Mentoring Award, 2010 recipient of the Irving S. Wright Award of Distinction, a 1997 Paul B. Beeson Emerging Leaders Career Development Award in Aging Scholar, and a 1994 AFAR Research Grant recipient, as well as Co-Investigator of the AFAR SuperAgers Family Study. He also directs the Institute for Aging Research at the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine and is the President of the Academy of Health and Lifespan Research.
Read “Why GLP-1’s Could Be an Anti-Aging Breakthrough” here.
For more insights from Dr. Barzilai into the current state of existing and emerging drug interventions to extend healthspan, watch our previous webinar, “The State of Gerotherapeutics: Next-Gen Interventions to Extend Healthy Living,” here.
